SEQUENCE LISTING

```
<110> MCGILL UNIVERSITY
      GAGNON, Martin
      SARAGOVI, H. Uri
<120> LIGANDS OF GANGLIOSIDE GD2 AND USES THEREOF
<130> 82873-5
<140> NOT YET ASSIGNED
<141> 2003-09-19
<150> US 60/412,492
<151> 2002-09-20
<160> 23
<170> PatentIn version 3.2
<210> 1
<211> 13
<212> PRT
<213> Artificial
<220>
<223> GD2 Ligand
<220>
<221> MISC_FEATURE
<222>
       (1)..(1)
<223> Xaa = Absent or Tyr or an analogue thereof.
<220>
<221> MOD RES
<222>
       (1)..(1)
       The N-terminal group may be of the formula H2N-, RHN-, or, RRN-,
<223>
       wherein R at each occurence is independently selected from (C1-C6)
       alkyl, (C1-C6) alkenyl, (C1-C6) alkynyl, substituted (C1-C6) alkyl,
        substituted (C1-C6) alkenyl, or substituted (C1-C6) alkynyl.
<220>
 <221> MISC FEATURE
 <222> (2)..(2)
 <223> Xaa = Absent or Cys or an analogue thereof.
 <220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> Xaa = Gly or Tyr or an analogue thereof.
 <220>
 <221> MISC FEATURE
 <222> (4)..(4)
 <223> Xaa = Gly or Cys or Tyr or an analogue thereof.
 <220>
 <221> MISC FEATURE
 <222> (5)..(5)
 <223> Xaa = Ile or Cys or an analogue thereof.
```

```
<220>
<221> MISC FEATURE
<222>
      (6)..(6)
<223> Xaa = Thr or Ala or an analogue thereof.
<220>
<221> MISC FEATURE
<222>
     (7)..(7)
<223> Xaa = Asn or an analogue thereof.
<220>
<221> MISC FEATURE
<222>
      (8)..(8)
<223> Xaa = Tyr or an analogue thereof.
<220>
<221> MISC FEATURE
<222>
      (9)..(9)
<223> Xaa = Asn or Gly or an analogue thereof.
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa = Ser or Cys or Val or Thr or an analogue thereof.
<220>
<221> MISC FEATURE
<222> (11)..(11)
<223> Xaa = Ala or Cys or Tyr or His or Ser or an analogue thereof.
<220>
<221> MISC_FEATURE
<222>
      (12)..(12)
<223> Xaa = absent or Leu or Cys or Tyr or an analogue thereof.
<220>
<221> MISC_FEATURE
<222> (13)..(13)
 <223> Xaa = absent or Met or Tyr or an analogue thereof.
<220>
 <221> MOD RES
 <222> (13)..(13)
 <223> C-terminal grp is of the formula -C(0)OH, -C(0)R, -C(0)OR,
       -C(O)NHR, -C(O)NRR; wherein each R is independently selected from
       (C1-C6) alkyl, (C1-C6) alkenyl, (C1-C6) alkynyl, substituted (C1-C6)
       alkyl, substituted (C1-C6) alkenyl, or substituted (C1-C6) alkynyl.
 <400> 1
 <210> 2
 <211> 13
 <212> PRT
 <213> Artificial
 <220>
 <223> GD2 Ligand
```

```
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Absent or Tyr or an analogue thereof.
<220>
<221> MISC FEATURE
<222> (2)..(2)
<223> Xaa = Absent or Cys or an analogue thereof.
<220>
<221> MISC FEATURE
<222> (3)..(3)
<223> Xaa = Gly or Tyr or an analogue thereof.
<220>
<221> MISC FEATURE
·<222> (4)..(4)
<223> Xaa = Gly or Cys or Tyr or an analogue thereof.
<220>
<221> MISC FEATURE
<222> (5)..(5)
<223> Xaa = Ile or Cys or an analogue thereof.
<220>
<221> MISC FEATURE
<222> (6)..(6)
<223> Xaa = Thr or Ala or an analogue thereof.
<220>
<221> MISC FEATURE
<222> (7)..(7)
<223> Xaa = Asn or an analogue thereof.
<220>
<221> MISC FEATURE
<222>
       (8)..(8)
<223> Xaa = Tyr or an analogue thereof.
<220>
<221> MISC_FEATURE
<222>
       (9)..(9)
<223> Xaa = Asn or Gly or an analogue thereof.
<220>
 <221> MISC FEATURE
 <222>
       (10)..(10)
 <223> Xaa = Ser or Cys or Val or Thr or an analogue thereof.
 <220>
 <221> MISC_FEATURE
 <222>
       (11)..(11)
 <223> Xaa = Ala or Cys or Tyr or His or Ser or an analogue thereof.
 <220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> Xaa = Absent or Leu or Cys or Tyr or an analogue thereof.
```

```
<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Xaa = Absent or Met or Tyr or an analogue thereof.
<400> 2
5
<210> 3
<211> 11
<212> PRT
<213> Artificial
<220>
<223> GD2 Ligand
<400> 3
Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met
               5
1
<210> 4
<211> 13
<212> PRT
<213> Artificial
<220>
<223> GD2 Ligand
<400> 4
Tyr Cys Gly Gly Ile Thr Asn Tyr Asn Ser Ala Cys Tyr
<210> 5
<211> 10
<212> PRT
<213> Artificial
 <220>
 <223> GD2 Ligand
 <400> 5
 Tyr Cys Ile Thr Asn Tyr Asn Ser Cys Tyr
 1 5
                                   10
 <210> 6
 <211> 11
 <212> PRT
 <213> Artificial
 <220>
 <223> GD2 Ligand
 Tyr Cys Gly Gly Ile Thr Asn Tyr Asn Cys Tyr
               5
```

```
<210> 7
<211> 10
<212> PRT
<213> Artificial
<220>
<223> GD2 Ligand
<400> 7
Tyr Cys Thr Asn Tyr Gly Val His Cys Tyr
               5
<210> 8
<211> 9
<212> PRT
<213> Artificial
<220>
<223> GD2 Ligand
<400> 8
Tyr Cys Thr Asn Tyr Gly Val Cys Tyr
             5
<210> 9
<211> 9
<212> PRT
<213> Artificial
<220>
<223> GD2 Ligand
 <400> 9
Gly Gly Ile Ala Asn Tyr Asn Thr Ser
                 5
<210> 10
<211> 11
<212> PRT
<213> Artificial
 <220>
 <223> GD2 Ligand
 <400> 10
 Tyr Cys Gly Gly Ile Ala Asn Tyr Asn Cys Tyr
                 5
 <210> 11
 <211> 13
 <212> PRT
 <213> Artificial
 <220>
 <223> GD2 Ligand
```

```
<400> 11
Tyr Cys Gly Gly Ile Ala Asn Tyr Asn Thr Ser Cys Tyr
<210> 12
<211> 10
<212> PRT
<213> Artificial
<220>
<223> GD2 Ligand
<400> 12
Tyr Cys Ile Ala Asn Tyr Asn Thr Cys Tyr
<210> 13
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Spanning sequence for peptide analogs that actively inhibit
       GD2-mAb 3F8 interactions.
<400> 13
Ile Thr Asn Tyr Asn
<210> 14
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Spanning sequence for peptide analogs that actively inhibit
       GD2-mAb 3F8 interactions.
<400> 14
Ile Ala Asn Tyr Asn
<210> 15
<211> 11
<212> PRT
<213> Artificial
<220>
<223> Peptide Mimic
<220>
<221> MISC_FEATURE
 <222> (1)..(11)
<223> Peptide is cyclic.
```

```
Cys Gly Gly Ile Thr Asn Tyr Asn Ser Ala Cys
<210> 16
<211> 8
<212> PRT
<213> Artificial
<220>
<223> Peptide Mimic
<220>
<221> MISC_FEATURE
<222> (1)..(8)
<223> Peptide is cyclic.
<400> 16
Cys Ile Thr Asn Tyr Asn Ser Cys
                5
<210> 17
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Peptide Mimic
<220>
<221> MISC_FEATURE
<222> (1)..(9)
<223> Peptide is cyclic.
<400> 17
Cys Gly Gly Ile Thr Asn Tyr Asn Cys
<210> 18
<211> 8
<212> PRT
<213> Artificial
<220>
<223> Peptide Mimic
 <220>
 <221> MISC FEATURE
 <222> (1)..(8)
 <223> Peptide is cyclic.
 <400> 18
 Cys Thr Asn Tyr Gly Val His Cys
```

PCT/CA2003/001389

```
<210> 19
<211> 7
<212> PRT
<213> Artificial
<220>
<223> Peptide Mimic
<220>
<221> MISC_FEATURE
<222> (1)..(7)
<223> Peptide is cyclic.
<400> 19
Cys Thr Asn Tyr Gly Val Cys
<210> 20
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Peptide Mimic
<220>
<221> MISC_FEATURE
<222> (1)..(9)
<223> Peptide is cyclic.
<400> 20
Cys Gly Gly Ile Ala Asn Tyr Asn Cys
<210> 21
<211> 11
<212> PRT
<213> Artificial
<220>
<223> Peptide Mimic
<400> 21
Cys Gly Gly Ile Ala Asn Tyr Asn Thr Ser Cys
                 5
<210> 22
<211> 8
<212> PRT
<213> Artificial
<220>
<223> Peptide mimic.
<220>
<221> MISC_FEATURE
<222> (1)..(8)
<223> Peptide is cyclic.
```

WO 2004/026895

<400> 22 Cys Ile Ala Asn Tyr Asn Thr Cys 1 5

<210> 23

<211> 1358

<212> PRT

<213> Homo sapiens

<400> 23

Met Gly Ala Asp Gly Glu Thr Val Val Leu Lys Asn Met Leu Ile Gly
1 5 10 15

Ile Asn Leu Ile Leu Gly Ser Met Ile Lys Pro Ser Glu Cys Gln 20 25 30

Leu Glu Val Thr Thr Glu Arg Val Gln Arg Gln Ser Val Glu Glu 35 40 45

Gly Gly Ile Ala Asn Tyr Asn Thr Ser Ser Lys Glu Gln Pro Val Val 50 55 60

Phe Asn His Val Tyr Asn Ile Asn Val Pro Leu Asp Asn Leu Cys Ser 65 70 75 80

Ser Gly Leu Glu Ala Ser Ala Glu Glu Val Ser Ala Glu Asp Glu 85 90 95

Thr Leu Ala Glu Tyr Met Gly Gln Thr Ser Asp His Glu Ser Gln Val 100 105 110

Thr Phe Thr His Arg Ile Asn Phe Pro Lys Lys Ala Cys Pro Cys Ala 115 120 125

Ser Ser Ala Gln Val Leu Gln Glu Leu Leu Ser Arg Ile Glu Met Leu 130 135 140

Glu Arg Glu Val Ser Val Leu Arg Asp Gln Cys Asn Ala Asn Cys Cys 145 150 155 160

Gln Glu Ser Ala Ala Thr Gly Gln Leu Asp Tyr Ile Pro His Cys Ser 165 170 175

Gly His Gly Asn Phe Ser Phe Glu Ser Cys Gly Cys Ile Cys Asn Glu 180 185 190

Gly Trp Phe Gly Lys Asn Cys Ser Glu Pro Tyr Cys Pro Leu Gly Cys 195 200 205

Ser Ser Arg Gly Val Cys Val Asp Gly Gln Cys Ile Cys Asp Ser Glu 210 215 220

Tyr Ser Gly Asp Asp Cys Ser Glu Leu Arg Cys Pro Thr Asp Cys Ser 225 230 235 240

Ser Arg Gly Leu Cys Val Asp Gly Glu Cys Val Cys Glu Glu Pro Tyr 245 250 255

Thr Gly Glu Asp Cys Arg Glu Leu Arg Cys Pro Gly Asp Cys Ser Gly 265 Lys Gly Arg Cys Ala Asn Gly Thr Cys Leu Cys Glu Glu Gly Tyr Val Gly Glu Asp Cys Gly Gln Arg Gln Cys Leu Asn Ala Cys Ser Gly Arg Gly Gln Cys Glu Glu Gly Leu Cys Val Cys Glu Glu Gly Tyr Gln Gly Pro Asp Cys Ser Ala Val Ala Pro Pro Glu Asp Leu Arg Val Ala Gly 330 Ile Ser Asp Arg Ser Ile Glu Leu Glu Trp Asp Gly Pro Met Ala Val 345 Thr Glu Tyr Val Ile Ser Tyr Gln Pro Thr Ala Leu Gly Gly Leu Gln 360 Leu Gln Gln Arg Val Pro Gly Asp Trp Ser Gly Val Thr Ile Thr Glu 375 Leu Glu Pro Gly Leu Thr Tyr Asn Ile Ser Val Tyr Ala Val Ile Ser 390 Asn Ile Leu Ser Leu Pro Ile Thr Ala Lys Val Ala Thr His Leu Ser 405 Thr Pro Gln Gly Leu Gln Phe Lys Thr Ile Thr Glu Thr Thr Val Glu 425 Val Gln Trp Glu Pro Phe Ser Phe Ser Phe Asp Gly Trp Glu Ile Ser 435 Phe Ile Pro Lys Asn Asn Glu Gly Gly Val Ile Ala Gln Val Pro Ser Asp Val Thr Ser Phe Asn Gln Thr Gly Leu Lys Pro Gly Glu Glu Tyr 465 Ile Val Asn Val Val Ala Leu Lys Glu Gln Ala Arg Ser Pro Pro Thr Ser Ala Ser Val Ser Thr Val Ile Asp Gly Pro Thr Gln Ile Leu Val Arg Asp Val Ser Asp Thr Val Ala Phe Val Glu Trp Ile Pro Pro Arg Ala Lys Val Asp Phe Ile Leu Leu Lys Tyr Gly Leu Val Gly Glu 535 Gly Gly Arg Thr Thr Phe Arg Leu Gln Pro Pro Leu Ser Gln Tyr Ser Val Gln Ala Leu Arg Pro Gly Ser Arg Tyr Glu Val Ser Val Ser Ala 565 570

Val Arg Gly Thr Asn Glu Ser Asp Ser Ala Thr Thr Gln Phe Thr Thr Glu Ile Asp Ala Pro Lys Asn Leu Arg Val Gly Ser Arg Thr Ala Thr 600 Ser Leu Asp Leu Glu Trp Asp Asn Ser Glu Ala Glu Val Gln Glu Tyr 615 Lys Val Val Tyr Ser Thr Leu Ala Gly Glu Gln Tyr His Glu Val Leu 630 Val Pro Arg Gly Ile Gly Pro Thr Thr Arg Ala Thr Leu Thr Asp Leu 650 Val Pro Gly Thr Glu Tyr Gly Val Gly Ile Ser Ala Val Met Asn Ser Gln Gln Ser Val Pro Ala Thr Met Asn Ala Arg Thr Glu Leu Asp Ser Pro Arg Asp Leu Met Val Thr Ala Ser Ser Glu Thr Ser Ile Ser Leu Ile Trp Thr Lys Ala Ser Gly Pro Ile Asp His Tyr Arg Ile Thr Phe Thr Pro Ser Ser Gly Ile Ala Ser Glu Val Thr Val Pro Lys Asp Arg 725 730 Thr Ser Tyr Thr Leu Thr Asp Leu Glu Pro Gly Ala Glu Tyr Ile Ile 745 Ser Val Thr Ala Glu Arg Gly Arg Gln Gln Ser Leu Glu Ser Thr Val 760 Asp Ala Phe Thr Gly Phe Arg Pro Ile Ser His Leu His Phe Ser His Val Thr Ser Ser Ser Val Asn Ile Thr Trp Ser Asp Pro Ser Pro Pro 790 795 Ala Asp Arg Leu Ile Leu Asn Tyr Ser Pro Arg Asp Glu Glu Glu Glu 810 Met Met Glu Val Ser Leu Asp Ala Thr Lys Arg His Ala Val Leu Met 820 825 Gly Leu Gln Pro Ala Thr Glu Tyr Ile Val Asn Leu Val Ala Val His Gly Thr Val Thr Ser Glu Pro Ile Val Gly Ser Ile Thr Thr Gly Ile Asp Pro Pro Lys Asp Ile Thr Ile Ser Asn Val Thr Lys Asp Ser Val Met Val Ser Trp Ser Pro Pro Val Ala Ser Phe Asp Tyr Tyr Arg Val 890

Ser Tyr Arg Pro Thr Gln Val Gly Arg Leu Asp Ser Ser Val Val Pro 900 905 910

- Asn Thr Val Thr Glu Phe Thr Ile Thr Arg Leu Asn Pro Ala Thr Glu 915 920 925
 - Tyr Glu Ile Ser Leu Asn Ser Val Arg Gly Arg Glu Glu Ser Glu Arg 930 935 940
 - Ile Cys Thr Leu Val His Thr Ala Met Asp Asn Pro Val Asp Leu Ile 945 950 955 960
 - Ala Thr Asn Ile Thr Pro Thr Glu Ala Leu Leu Gln Trp Lys Ala Pro 965 970 975
 - Val Gly Glu Val Glu Asn Tyr Val Ile Val Leu Thr His Phe Ala Val 980 985 990
 - Ala Gly Glu Thr Ile Leu Val Asp Gly Val Ser Glu Glu Phe Arg Leu 995 1000 1005
 - Val Asp Leu Leu Pro Ser Thr His Tyr Thr Ala Thr Met Tyr Ala 1010 1015 1020
 - Thr Asn Gly Pro Leu Thr Ser Gly Thr Ile Ser Thr Asn Phe Ser 1025 1030 1035
 - Thr Leu Leu Asp Pro Pro Ala Asn Leu Thr Ala Ser Glu Val Thr 1040 1045 1050
 - Arg Gln Ser Ala Leu Ile Ser Trp Gln Pro Pro Arg Ala Glu Ile 1055 1060 1065
 - Glu Asn Tyr Val Leu Thr Tyr Lys Ser Thr Asp Gly Ser Arg Lys 1070 1080
 - Glu Leu Ile Val Asp Ala Glu Asp Thr Trp Ile Arg Leu Glu Gly 1085 1090 1095
 - Leu Leu Glu Asn Thr Asp Tyr Thr Val Leu Leu Gln Ala Ala Gln 1100 1105 1110
 - Asp Thr Thr Trp Ser Ser Ile Thr Ser Thr Ala Phe Thr Thr Gly 1115 1120 1125
 - Gly Arg Val Phe Pro His Pro Gln Asp Cys Ala Gln His Leu Met 1130 1140
 - Asn Gly Asp Thr Leu Ser Gly Val Tyr Pro Ile Phe Leu Asn Gly 1145 1150 1155
 - Glu Leu Ser Gln Lys Leu Gln Val Tyr Cys Asp Met Thr Thr Asp 1160 1165 1170
 - Gly Gly Gly Trp Ile Val Phe Gln Arg Arg Gln Asn Gly Gln Thr 1175 1180 1185
 - Asp Phe Phe Arg Lys Trp Ala Asp Tyr Arg Val Gly Phe Gly Asn 1190 1195 1200

Val Glu Asp Glu Phe Trp Leu Gly Leu Asp Asn Ile His Arg Ile Thr Ser Gln Gly Arg Tyr Glu Leu Arg Val Asp Met Arg Asp Gly Gln Glu Ala Ala Phe Ala Ser Tyr Asp Arg Phe Ser Val Glu Asp Ser Arg Asn Leu Tyr Lys Leu Arg Ile Gly Ser Tyr Asn Gly Thr Ala Gly Asp Ser Leu Ser Tyr His Gln Gly Arg Pro Phe Ser Thr Glu Asp Arg Asp Asn Asp Val Ala Val Thr Asn Cys Ala Met Ser Tyr Lys Gly Ala Trp Trp Tyr Lys Asn Cys His Arg Thr Asn Leu Asn Gly Lys Tyr Gly Glu Ser Arg His Ser Gln Gly Ile Asn Trp Tyr His Trp Lys Gly His Glu Phe Ser Ile Pro Phe Val Glu Met Lys Met Arg Pro Tyr Asn His Arg Leu Met Ala Gly Arg Lys Arg Gln Ser Leu Gln Phe